+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2012-01-16Number of Pages: 28

China Osteoporosis Market Analysis and Forecast 2007 - 2015

Table of Content

1. Executive Summary

2. China Osteoporosis Market
   2.1. Market Overview
   2.2. Growth Drivers and Opportunities
   2.3. Recent Market Developments
   2.4. Competitive Strategies
   2.5. Future Outlook
   2.6. Driving Factor Analysis of China Osteoporosis Market
        2.6.1. Demand Side Drivers
        2.6.2. Supply Side Drivers
        2.6.3. Restraints
        2.6.4. Opportunities
        2.6.5. Key Competitive Points

3. China Osteoporosis Market Share (2007 - 2015)
   3.1. By Drug Class - Osteoporosis Market Share & Forecast
   3.2. By Drug Market Share - Osteoporosis Market Share & Forecast

4. Osteoporosis Drugs Classes Market & Forecast (2007 - 2015)
   4.1. China Bisphosphonate Market & Forecast
   4.2. China Selective Estrogen Receptor Modulators (SERM) Market & Forecast
   4.3. China Parathyroid Hormone (PTH) Market & Forecast
   4.4. China Calcitonin Market & Forecast

5. Osteoporosis Drugs Market Analysis & Forecast (2007 - 2015)
   5.1. Bisphosphonate Drugs Market Analysis
        5.1.1. Fosamax (Alendronate)
        5.1.2. Bonviva/Boniva (Ibandronic Acid)
        5.1.3. Reclast/Aclasta
        5.1.4. Actonel (Risedronate)
   5.2. SERMs Drugs Market Analysis
        5.2.1. Evista (Raloxifene)
        5.2.2. Viviant/ Conbriza (Bazedoxifene)
   5.3. Parathyroid Hormone Drugs Market Analysis
        5.3.1. Forteo
   5.4. Calcitonin Drugs Market Analysis
        5.4.1. Miacalcin
   5.5. Prolia (Denosumab)

6. Pipeline Drugs in Osteoporosis Market Analysis
   6.1. Odanacatib (MK 0822)
   6.2. Aprela (Bazedoxifene)

7. Recommendations
   7.1. Market Strategy for Success
   7.2. Barriers to be Considered
   7.3. Future Assumption


 
 
Back To Top